➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

APIXABAN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

DrugPatentWatch® Litigation and Generic Entry Outlook for Apixaban

A generic version of APIXABAN was approved as apixaban by ACCORD HLTHCARE on July 28th, 2020.

  Get Started for $10

Drug patent expirations by year for APIXABAN
Drug Sales Revenue Trends for APIXABAN

See drug sales revenues for APIXABAN

Recent Clinical Trials for APIXABAN

Identify potential brand extensions & 505(b)(2) entrants

Dt&SanomedicsPhase 2
Korea University Guro HospitalPhase 2
The University of Cambridge (joint Sponsor)Phase 3

See all APIXABAN clinical trials

Pharmacology for APIXABAN
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Paragraph IV (Patent) Challenges for APIXABAN
Tradename Dosage Ingredient NDA Submissiondate
ELIQUIS TABLET;ORAL apixaban 202155 2016-12-28

US Patents and Regulatory Information for APIXABAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare APIXABAN apixaban TABLET;ORAL 210180-001 Jul 28, 2020 AB RX No No   Get Started for $10   Get Started for $10   Get Started for $10
Micro Labs APIXABAN apixaban TABLET;ORAL 210013-001 Dec 23, 2019 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
Bionpharma Inc APIXABAN apixaban TABLET;ORAL 210152-002 Apr 8, 2020 DISCN No No   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.